CRISPR Unlocks Sweeter Tomatoes Without Yield Loss
Carbon
Nov. 19, 2024
Relevant Interviews, Webinar and Trial Updates posted by CRISPR Medicine News.
Always stay updated with the free CMN Newsletter.
Acrobat Genomics
Company Type: Therapeutic development
Main focus: Developing CRISPR-based technologies to advance curative therapeutics for genetic diseases with limited treatment options
Company stage: Pre-clinical
Diseases: Interstitial lung diseases and other genetic diseases
Genome-editing tool: CRISPR-Cas
Funding stage: Pre-seed
Location: San-Francisco, California, USA
Website: https://www.acrobatgenomics.com/
Pipeline:
Partners:
Acrobat Genomics is a biotechnology startup that focuses on developing advanced gene-editing therapies for genetic diseases, using a proprietary platform for precise genetic modification. Founded in 2022, Acrobat Genomics has entered collaborations with institutions including Stanford Medicine and NanoString to target interstitial lung diseases. The company has won awards, such as the Golden Ticket from Nitto Innovations, supporting its growth and innovation in genomic medicine development.
